Cleare, Anthony J, Messa, Cristina, Rabiner, Eugenii A et al. · Biological psychiatry · 2005 · DOI
This study used brain imaging to measure a specific receptor (5-HT1A) that helps regulate serotonin, a chemical messenger in the brain. Researchers compared 10 ME/CFS patients with 10 healthy people and found that ME/CFS patients had significantly fewer of these receptors, especially in a brain region called the hippocampus (involved in memory and emotion). This suggests that serotonin regulation in the brain may work differently in ME/CFS.
This is one of the few direct in vivo measurements of serotonin receptor function in ME/CFS, providing objective biological evidence of altered central nervous system chemistry. Understanding neurochemical abnormalities may help explain cognitive and mood symptoms and could guide development of targeted treatments.
This study does not establish whether reduced 5-HT1A receptors cause ME/CFS symptoms or result from them. It does not prove that serotonin-targeting medications will be effective, and the small sample size limits generalizability. The cross-sectional design cannot determine whether receptor changes precede symptom onset or develop over the course of illness.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Spotted an error in this entry? Report it →